Digestive Diseases and Sciences

, Volume 51, Issue 3, pp 603–609 | Cite as

A Long-Term Glycyrrhizin Injection Therapy Reduces Hepatocellular Carcinogenesis Rate in Patients with Interferon-Resistant Active Chronic Hepatitis C: A Cohort Study of 1249 Patients

  • Kenji Ikeda
  • Yasuji Arase
  • Masahiro Kobayashi
  • Satoshi Saitoh
  • Takashi Someya
  • Tetsuya Hosaka
  • Hitomi Sezaki
  • Norio Akuta
  • Yoshiyuki Suzuki
  • Fumitaka Suzuki
  • Hiromitsu Kumada
Gastrointestinal Oncology

Abstract

To elucidate the influence of a glycyrrhizin therapy on hepatocarcinogenesis rate in interferon (IFN)-resistant hepatitis C, we retrospectively analyzed 1249 patients with chronic hepatitis with or without cirrhosis. Among 346 patients with high alanine transaminase value (twice or more of upper limit of normal), 244 patients received intravenous glycyrrhizin injection and 102 patients did not, after judgment of IFN resistance. Crude carcinogenesis rates in the treated and untreated group were 13.3%, 26.0% at the 5th year, and 21.5% and 35.5% at the 10th year, respectively (P = .0210). Proportional hazard analysis using time-dependent covariates disclosed that glycyrrhizin treatment significantly decreased the hepatocarcinogenesis rate (hazard ratio 0.49, 95% confidence interval 0.27–0.86, P = .014) after adjusting the background features with significant covariates. Glycyrrhizin injection therapy significantly decreased the incidence of hepatocellular carcinoma in patients with IFN-resistant active chronic hepatitis C, whose average aminotransferase value was twice or more of upper limit of normal after interferon.

Key Words

chronic hepatitis hepatitis C virus glycyrrhizin hepatocellular carcinogenesis cancer prevention 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bruix J, Calvet X, Costa J, et al.: Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 2:1004–1006, 1989PubMedGoogle Scholar
  2. 2.
    Colombo M, Kuo G, Choo QL, et al.: Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 2:1006–1008, 1989PubMedGoogle Scholar
  3. 3.
    Hasan F, Jeffers LJ, Medina MD, et al.: Hepatitis C-associated hepatocellular carcinoma. Hepatology 12:589–591, 1990PubMedGoogle Scholar
  4. 4.
    Kew MC, Houghton M, Choo QL, et al.: Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma. Lancet 335:873–874, 1990CrossRefPubMedGoogle Scholar
  5. 5.
    Ikeda K, Saitoh S, Koida I, et al.: A multivariate analysis of risk factors for hepatocellular carcinogenesis—a prospective observation of 795 cases with viral and alcoholic cirrhosis. Hepatology 18:47–53, 1993CrossRefPubMedGoogle Scholar
  6. 6.
    Kasahara A, Hayashi N, Mochizuki K, et al.: Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 27:1394–1402, 1998CrossRefPubMedGoogle Scholar
  7. 7.
    Ikeda K, Saitoh S, Arase Y, et al.: Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C—a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology 29:1124–1130, 1999PubMedGoogle Scholar
  8. 8.
    Yabu K, Kiyosawa K, Mori H, et al.: Serum collagen type IV for the assessment of fibrosis and resistance to interferon therapy in chronic hepatitis C. Scand J Gastroenterol 29:474–479, 1994PubMedGoogle Scholar
  9. 9.
    Nishiguchi S, Kuroki T, Nakatani S, et al.: Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346:1051–1055, 1995CrossRefPubMedGoogle Scholar
  10. 10.
    Mazzella G, Accogli E, Sottili S, et al.: Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 24:141–147, 1996CrossRefPubMedGoogle Scholar
  11. 11.
    Benvegnu L, Chemello L, Noventa F, et al.: A. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 83:901–909, 1998PubMedGoogle Scholar
  12. 12.
    Oka H, Yamamoto S, Kuroki T, et al.: Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9). Cancer 76:743–749, 1995PubMedGoogle Scholar
  13. 13.
    Tarao K, Rino Y, Ohkawa S, et al.: Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis. Cancer 86:589–595, 1999CrossRefPubMedGoogle Scholar
  14. 14.
    Fujisawa K, Watanabe Y, Kimura K: Therapeutic approach to chronic active hepatitis with glycyrrhizin. Asian Med J 23:745–756, 1980Google Scholar
  15. 15.
    Suzuki H, Ohta Y, Takino T, et al.: Effects of glycyrrhizin on biochemical tests in patients with chronic hepatitis. Double blind trial. Asian Med J 26:423–438, 1983Google Scholar
  16. 16.
    Wildhirt E: Experience in Germany with glycyrrhizinic acid for the treatment of chronic viral hepatitis. In: Viral Hepatitis and Liver Disease 658–661, 1994, Springer Verlag, GermanyGoogle Scholar
  17. 17.
    Rossum TGJ van, Vulto AG, Hop WCJ, et al.: Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial. J Gastroenterol Hepatol 14:1093–1099, 1999CrossRefPubMedGoogle Scholar
  18. 18.
    Arase Y, Ikeda K, Murashima N, et al.: The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 79:1494–1500, 1997CrossRefPubMedGoogle Scholar
  19. 19.
    Desmet VJ, Gerber M, Hoofnagle JH, et al.: Classification of chronic hepatitis: diagnosis, grading, and staging. Hepatology 19:1513–1520, 1994CrossRefPubMedGoogle Scholar
  20. 20.
    Kaplan EL, Meier P: Nonparametric estimation for incomplete observation. J Am Stat Assoc 53:457–481, 1958Google Scholar
  21. 21.
    Cox DR: Regression models and life tables. J R Stat Soc 34:248–275, 1972Google Scholar
  22. 22.
    SPSS Inc. SPSS for Windows version 11.0 manual. Chicago, SPSS Inc., 2001Google Scholar
  23. 23.
    Nevens F, Goubau P, Van Eyken P, et al.: Treatment of decompensated viral hepatitis B-induced cirrhosis with low doses of interferon alpha. Liver 13:15–19, 1993PubMedGoogle Scholar
  24. 24.
    Tarao K, Takemiya S, Tamai S, et al.: Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. Cancer, 79:688–694, 1997CrossRefPubMedGoogle Scholar
  25. 25.
    Gaeta GB, Rapicetta M, Sardaro C, et al.: High prevalence of co-occurrence of anti-HCV and anti-HBc antibodies in chronic hepatitis patients from southern Italy. Ital J Gastroenterol 22:350–351, 1990PubMedGoogle Scholar
  26. 26.
    Yu MC, Yuan JM, Ross RK, et al.: Presence of antibodies to hepatitis B surface antigen is associated with an excess risk for hepatocellular carcinoma among non-Asians in Los Angeles county, California. Hepatology 25:226–228, 1997PubMedGoogle Scholar
  27. 27.
    Koike K, Kobayashi M, Gondo M, et al.: Hepatitis B virus DNA is frequently found in liver biopsy samples from hepatitis C virus-infected chronic hepatitis patients. J Med Virol 54:249–255, 1998CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2006

Authors and Affiliations

  • Kenji Ikeda
    • 1
    • 2
    • 3
  • Yasuji Arase
    • 1
    • 2
  • Masahiro Kobayashi
    • 1
    • 2
  • Satoshi Saitoh
    • 1
    • 2
  • Takashi Someya
    • 1
    • 2
  • Tetsuya Hosaka
    • 1
    • 2
  • Hitomi Sezaki
    • 1
    • 2
  • Norio Akuta
    • 1
    • 2
  • Yoshiyuki Suzuki
    • 1
    • 2
  • Fumitaka Suzuki
    • 1
    • 2
  • Hiromitsu Kumada
    • 1
    • 2
  1. 1.Department of GastroenterologyToranomon HospitalTokyoJapan
  2. 2.Okinaka Memorial Institute for Medical ResearchTokyoJapan
  3. 3.Department of GastroenterologyToranomon HospitalTokyoJapan

Personalised recommendations